Emergent BioSolutions Inc. (EBS) Key Metrics
EBS valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $327.1M
- Enterprise value
- $784.1M
- P/E (TTM)
- — 10-yr median 28.3
- Forward P/E
- 23.0
- PEG ratio
- 0.38
- Price / sales
- 0.4 10-yr median 1.9
- Price / book
- 1.0 10-yr median 2.0
- EV / EBITDA
- 5.2 10-yr median 12.7
- Dividend yield
- —
- Beta
- 2.29
EBS key metrics, 2016–2025
Fiscal year ended December 31, 2025 · U.S. dollarsEBS valuation Price multiples at each fiscal year-end price.
EBS returns How much profit the business earns on the capital it uses.
EBS per-share figures Results divided by the shares outstanding at year-end.
EBS financial health Debt, liquidity and how easily interest is covered.
EBS efficiency & capital use Working capital cycle and where the cash goes.
EBS valuation history
EBS returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
EBS debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
EBS cash returned to shareholders
EBS price vs earnings per share
EBS key metrics
2016–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Market capitalization | $700.8M | $506.7M | $122.9M | $591.7M | $2.35B | $4.82B | $2.83B | $3.05B | $2.34B | $1.62B |
| Enterprise value | $1.07B | $1.08B | $871.4M | $1.38B | $2.65B | $5.12B | $3.50B | $3.73B | $2.22B | $1.62B |
| P/E ratio | 13.3 | — | — | — | 10.7 | 15.8 | 51.9 | 48.6 | 28.3 | 31.3 |
| Price / sales | 0.9 | 0.5 | 0.1 | 0.5 | 1.3 | 3.1 | 2.6 | 3.9 | 4.2 | 3.3 |
| Price / book | 1.3 | 1.0 | 0.2 | 0.4 | 1.5 | 3.3 | 2.6 | 3.0 | 2.6 | 2.7 |
| Price / free cash flow | 4.5 | 14.2 | — | — | 24.5 | 12.2 | 28.0 | — | 15.3 | — |
| Price / operating cash flow | 4.1 | 8.6 | — | — | 7.3 | 9.0 | 15.0 | 72.9 | 11.2 | 30.3 |
| EV / sales | 1.4 | 1.0 | 0.8 | 1.2 | 1.5 | 3.2 | 3.2 | 4.8 | 4.0 | 3.3 |
| EV / EBITDA | 4.5 | 19.1 | — | 40.5 | 5.2 | 8.3 | 13.4 | 24.0 | 12.7 | 12.2 |
| EV / free cash flow | 6.8 | 30.3 | — | — | 27.5 | 13.0 | 34.6 | — | 14.5 | — |
| Earnings yield | 7.5% | −37.6% | −618.9% | −35.8% | 9.3% | 6.3% | 1.9% | 2.1% | 3.5% | 3.2% |
| Free cash flow yield | 22.4% | 7.1% | −209.9% | −25.3% | 4.1% | 8.2% | 3.6% | −1.0% | 6.6% | −1.4% |
| Dividend yield | — | — | 4.1% | — | 0.7% | 0.4% | 0.0% | — | 0.0% | 0.0% |
| Shareholder yield (dividends + buybacks) | 3.6% | 0.0% | 70.9% | 13.9% | 5.2% | 0.7% | 0.3% | 0.0% | 1.4% | 0.1% |
| Share price at fiscal year-end | $12.36 | $9.56 | $2.40 | $11.81 | $43.47 | $89.60 | $53.95 | $59.28 | $46.47 | $32.84 |
| Per share | ||||||||||
| Revenue per share | $13.10 | $19.69 | $20.49 | $22.31 | $32.78 | $29.32 | $21.11 | $15.22 | $11.14 | $9.91 |
| Earnings per share | $0.93 | −$3.60 | −$14.85 | −$4.22 | $4.06 | $5.68 | $1.04 | $1.22 | $1.64 | $1.05 |
| Operating cash flow per share | $3.01 | $1.11 | −$4.03 | −$0.68 | $5.94 | $9.98 | $3.59 | $0.81 | $4.14 | $1.08 |
| Free cash flow per share | $2.77 | $0.68 | −$5.04 | −$2.99 | $1.78 | $7.34 | $1.93 | −$0.59 | $3.05 | −$0.46 |
| Cash per share | $3.62 | $1.88 | $2.18 | $12.83 | $10.65 | $11.55 | $3.21 | $2.18 | $3.54 | $5.50 |
| Book value per share | $9.22 | $9.11 | $12.68 | $27.70 | $29.79 | $26.90 | $20.77 | $19.67 | $18.13 | $12.08 |
| Tangible book value per share | $1.52 | −$0.35 | −$2.65 | $8.80 | $14.45 | $9.61 | $1.53 | −$1.18 | $14.78 | $10.57 |
| Dividends per share | — | — | $0.10 | — | $0.29 | $0.33 | $0.02 | — | $0.00 | $0.00 |
| Capex per share | $0.24 | $0.43 | $1.01 | $2.31 | $4.16 | $2.64 | $1.66 | $1.40 | $1.09 | $1.55 |
| Debt per share | $10.09 | $12.76 | $16.80 | $28.47 | $16.10 | $17.16 | $15.97 | $15.46 | $1.12 | $5.43 |
| Shares outstanding | 56.7M | 53.0M | 51.2M | 50.1M | 54.1M | 53.8M | 52.4M | 51.4M | 50.3M | 49.3M |
| Change in shares outstanding | +7.0% | +3.5% | +2.2% | −7.4% | +0.6% | +2.7% | +1.9% | +2.1% | +2.0% | +4.4% |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | 10.5% | −33.7% | −74.7% | −14.1% | 14.4% | 24.1% | 5.2% | 6.5% | 11.0% | 8.2% |
| Return on invested capital (ROIC) | 7.2% | −7.0% | −32.2% | −6.6% | 13.5% | 18.6% | 4.7% | 5.6% | 12.5% | 10.8% |
| Return on assets (ROA) | 3.9% | −11.9% | −30.5% | −6.9% | 7.5% | 11.7% | 2.4% | 3.8% | 8.1% | 5.1% |
| Return on tangible assets | 6.0% | −21.5% | −73.2% | −9.5% | 10.3% | 15.7% | 4.1% | 5.4% | 9.2% | 5.8% |
| Free cash flow margin | 21.1% | 3.4% | −24.6% | −13.4% | 5.4% | 25.0% | 9.1% | −3.9% | 27.3% | −4.7% |
| Income quality (OCF / net income) | 3.24 | — | — | — | 1.46 | 1.76 | 3.45 | 0.67 | 2.52 | 1.03 |
| Financial health | ||||||||||
| Total debt | $572.1M | $676.1M | $860.2M | $1.43B | $871.0M | $923.0M | $836.9M | $794.6M | $56.2M | $268.1M |
| Cash & short-term investments | $205.4M | $99.5M | $111.7M | $642.6M | $576.3M | $621.3M | $168.0M | $112.2M | $178.3M | $271.5M |
| Net debt | $366.7M | $576.6M | $748.5M | $783.8M | $294.7M | $301.7M | $668.9M | $682.4M | −$122.1M | −$3.4M |
| Debt / equity | 1.09 | 1.40 | 1.32 | 1.03 | 0.54 | 0.64 | 0.77 | 0.79 | 0.06 | 0.45 |
| Debt / assets | 0.43 | 0.49 | 0.47 | 0.45 | 0.29 | 0.32 | 0.36 | 0.36 | 0.05 | 0.28 |
| Net debt / EBITDA | 1.54 | 10.19 | — | 23.05 | 0.58 | 0.49 | 2.56 | 4.40 | −0.70 | −0.03 |
| Current ratio | 5.01 | 3.69 | 1.04 | 0.98 | 3.40 | 3.11 | 3.17 | 3.10 | 4.85 | 4.82 |
| Quick ratio | 2.41 | 1.77 | 0.54 | 0.70 | 2.47 | 2.31 | 2.14 | 2.07 | 3.42 | 4.12 |
| Interest coverage | 1.9 | -1.5 | -8.3 | -4.6 | 9.9 | 14.0 | 3.0 | 9.1 | 18.9 | 13.9 |
| Working capital | $530.3M | $436.3M | $28.2M | −$18.5M | $895.9M | $811.4M | $469.9M | $420.4M | $385.3M | $404.4M |
| Invested capital | $889.3M | $1.06B | $1.40B | $2.17B | $1.91B | $1.75B | $1.76B | $1.69B | $790.2M | $592.8M |
| Tangible asset value | $86.1M | −$18.7M | −$135.5M | $440.7M | $782.0M | $517.2M | $80.0M | −$60.4M | $743.6M | $521.3M |
| Net current asset value | −$133.5M | −$308.2M | −$494.4M | −$568.2M | −$76.3M | −$240.3M | −$552.6M | −$597.7M | $327.5M | $136.3M |
| Graham number | $13.87 | — | — | — | $52.15 | $58.65 | $22.05 | $23.23 | $25.87 | $16.90 |
| Graham net-net per share | −$6.27 | −$10.11 | −$14.74 | −$16.79 | −$7.18 | −$9.07 | −$14.37 | −$15.69 | $4.00 | $0.93 |
| Capital allocation | ||||||||||
| Dividends paid | — | — | $5.0M | — | $15.9M | $17.8M | $799,999 | — | $0 | $0 |
| Share buybacks (net) | $24.9M | $0 | $82.1M | $82.1M | $106.0M | $13.8M | $7.4M | $100,000 | $33.1M | $1.1M |
| Dividend payout ratio | — | — | — | — | 7.2% | 5.8% | 1.5% | — | 0.0% | 0.0% |
| Dividends + buybacks / free cash flow | 15.9% | 0.0% | — | — | 126.8% | 8.0% | 8.1% | — | 21.6% | — |
| Capex / revenue | 1.9% | 2.2% | 4.9% | 10.4% | 12.7% | 9.0% | 7.9% | 9.2% | 9.8% | 15.6% |
| Capex / operating cash flow | 8.1% | 39.0% | — | — | 70.1% | 26.4% | 46.2% | 172.5% | 26.3% | 142.6% |
| Capex / depreciation | 0.14 | 0.21 | 0.41 | 0.81 | 1.82 | 1.24 | 0.79 | 1.16 | 1.29 | 2.00 |
| Stock-based compensation / revenue | 2.2% | 1.7% | 2.2% | 4.0% | 2.4% | 3.3% | 2.4% | 3.0% | 2.7% | 3.8% |
| R&D / revenue | 7.2% | 6.8% | 10.6% | 16.9% | 13.3% | 15.1% | 20.5% | 18.3% | 17.4% | 21.9% |
| SG&A / revenue | 25.1% | 29.5% | 35.5% | 30.5% | 19.6% | 19.2% | 24.7% | 25.9% | 25.6% | 29.4% |
| Efficiency | ||||||||||
| Days sales outstanding | 58.6 | 60.4 | 60.9 | 71.5 | 52.5 | 58.6 | 88.7 | 95.3 | 95.8 | 103.0 |
| Days of inventory on hand | 304.8 | 175.0 | 179.9 | 196.9 | 121.3 | 135.3 | 125.5 | 137.7 | 142.7 | 112.9 |
| Days payables outstanding | 54.2 | 47.3 | 57.1 | 65.8 | 49.3 | 59.0 | 51.4 | 48.4 | 50.3 | 60.3 |
| Cash conversion cycle (days) | 309.2 | 188.1 | 183.7 | 202.6 | 124.4 | 134.9 | 162.8 | 184.6 | 188.3 | 155.6 |
| Receivables turnover | 6.22 | 6.04 | 5.99 | 5.10 | 6.96 | 6.23 | 4.11 | 3.83 | 3.81 | 3.54 |
| Payables turnover | 6.73 | 7.72 | 6.39 | 5.55 | 7.40 | 6.19 | 7.10 | 7.55 | 7.26 | 6.05 |
| Inventory turnover | 1.20 | 2.09 | 2.03 | 1.85 | 3.01 | 2.70 | 2.91 | 2.65 | 2.56 | 3.23 |
| Asset turnover | 0.55 | 0.65 | 0.42 | 0.36 | 0.61 | 0.61 | 0.49 | 0.47 | 0.55 | 0.49 |
| Average receivables | $119.3M | $172.8M | $175.1M | $219.1M | $254.9M | $253.1M | $268.9M | $204.3M | $147.3M | $137.9M |
| Average payables | $58.2M | $86.5M | $107.8M | $116.2M | $132.5M | $115.5M | $87.8M | $61.2M | $38.2M | $40.3M |
| Average inventory | $327.6M | $320.3M | $339.8M | $347.6M | $325.8M | $264.8M | $214.2M | $174.3M | $108.4M | $75.5M |
| Intangibles / total assets | 33.1% | 36.1% | 43.0% | 29.9% | 28.0% | 32.2% | 43.3% | 48.1% | 15.8% | 7.7% |
Computed from EBS's annual financial statements (latest annual report filed February 27, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
EBS valuation and financial ratios
At the end of fiscal 2025 (December 31, 2025), Emergent BioSolutions traded at 13.3 times earnings, against a 10-year median of 28.3. Emergent BioSolutions earned a return on equity of 10.5% and a return on invested capital of 7.2% in fiscal 2025. It ended the year with $572.1 million of debt and $205.4 million in cash and short-term investments, net debt of $366.7 million. It returned $24.9 million to shareholders: $0 in dividends and $24.9 million in share buybacks, 16% of free cash flow. The share count rose 14.9% from 49.3M to 56.7M over 9 years.
See the EBS income statement, the EBS chart for price history, or the EBS stock overview for the latest quote and news.
EBS key metrics FAQ
What is Emergent BioSolutions's P/E ratio?
Emergent BioSolutions traded at 13.3 times earnings at the end of fiscal 2025.
What is Emergent BioSolutions's EV/EBITDA?
Emergent BioSolutions's enterprise value was 4.5 times EBITDA at the end of fiscal 2025 (enterprise value $1.1 billion, EBITDA $237.9 million); the current EV/EBITDA is 5.2.
What is Emergent BioSolutions's return on equity?
Emergent BioSolutions's return on equity (ROE) was 10.5% in fiscal 2025: net income of $52.6 million on average shareholders' equity of $502.7 million.
What is Emergent BioSolutions's ROIC?
Emergent BioSolutions's return on invested capital was 7.2% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does Emergent BioSolutions have?
Emergent BioSolutions had total debt of $572.1 million at the end of fiscal 2025, a debt-to-equity ratio of 1.09 and $366.7 million of net debt (1.54 times EBITDA).
Does Emergent BioSolutions buy back its shares?
Yes. Emergent BioSolutions spent $24.9 million on net share repurchases in fiscal 2025 Shares outstanding changed +7.0% over the year, to 56.7M..
What is Emergent BioSolutions's free cash flow yield?
Emergent BioSolutions generated $156.8 million of free cash flow in fiscal 2025, a free cash flow yield of 22.4% on its market value at year-end ($700.8 million).
What is Emergent BioSolutions's current ratio?
Emergent BioSolutions's current ratio was 5.01 at the end of fiscal 2025: current assets were 5.01 times current liabilities.